Indications › Psychiatric conditions
GLP‑1 drugs in psychiatric conditions
Which incretin agents are being studied in psychiatric conditions, by whom, and when each trial is due to report. Conditions are grouped from the registry’s own wording, which records the same disease several ways.
- Trials on file
- 11
- Active
- 5
- Results scheduled
- 3
- Molecules studied
- 4
- Sponsors
- 9
No GLP‑1 or incretin drug is FDA-approved for psychiatric conditions. The trials below are studies, not approvals, and most drugs tested in a new condition never get approved for it.
No GLP-1 or incretin drug is approved for psychiatric conditions, so everything below is investigational. Most drugs tested in a new condition never reach approval for it, and a registration is not evidence of benefit. 7 of the 11 trials on file are phase 3 or later — the stage sized for a regulator to act on, against 4 still in early phases. 9 distinct sponsors are involved.
Molecules studied in this indication
exenatide · liraglutide · semaglutide · tirzepatide
Results due in this indication
| Est. completion | Drug | Trial | Phase | Participants |
|---|---|---|---|---|
| 2027-09 | semaglutide | Does Semaglutide Improve Depressive Symptoms in Patients With Major Depressive Disorder and Overweight or Obesity NCT07136714 · Nordsjaellands Hospital | P4 | 116 |
| 2028-02-01 | semaglutide | Individualized Pharmacological Approach to Obesity in Patients With Bipolar Disorder NCT07213466 · Mayo Clinic | P4 | 100 |
| 2028-08-01 | tirzepatide | Effects of Tirzepatide on Alcohol Intake in Patients Diagnosed With Schizophrenia and Alcohol Use Disorder NCT06939088 · Anders Fink-Jensen, MD, DMSci | P2 | 108 |
Trials on file
All 11 incretin trials recorded in this indication, active first.